Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company, today announced the launch of Oncology FACETS: an educational platform for healthcare providers that will address clinically impactful topics in gynecologic oncology.
Oncology FACETS is driven by a Steering Committee of experts in gynecologic oncology and offers content developed in collaboration with Mersana.
“Our goal is to create a destination where oncologists can find up-to-date, peer-reviewed educational content on emerging topics about ovarian, endometrial, cervical, and other gynecological cancers,” said one official.
“We believe Oncology FACETS will provide a valuable resource for physicians seeking to keep pace with this field’s rapidly evolving science and data.”
Each Oncology FACETS educational module is led by a Steering Committee member. The first module is “Current and Emerging Biomarkers in Gynecologic Cancer,” led by Dr. Rebecca C. Arend, a leading gynecologic
oncologist at the University of Alabama at Birmingham. The module is now available for download at OncologyFACETS.com.
Oncology FACETS will release new modules on a regular basis. The next module, planned to be released in December 2022, will focus on antibody-drug conjugates (ADCs) in gynecologic malignancies.
Said Mersana CEO Anna Protopapas, “We are proud to collaborate with this esteemed group of gynecologic oncologists to advance knowledge and patient care.
“Oncology FACETS is a natural extension of our commitment to driving innovation aimed at improving outcomes for women with gynecologic cancers.
MRSN shares popped 28 cents, or 4.4%, to $6.70.
